NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $3.88 -0.09 (-2.27%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.75▼$4.1050-Day Range$3.75▼$6.7452-Week Range$3.51▼$20.72Volume32,477 shsAverage Volume49,437 shsMarket Capitalization$114.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Telomir Pharmaceuticals alerts: Email Address Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Telomir Pharmaceuticals Stock (NASDAQ:TELO)Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Read More TELO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TELO Stock News HeadlinesJuly 2, 2024 | markets.businessinsider.comTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap IndexesJune 17, 2024 | globenewswire.comTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting PanelJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 30, 2024 | globenewswire.comTelomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1May 14, 2024 | investorplace.comTELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024April 16, 2024 | globenewswire.comTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.April 2, 2024 | globenewswire.comTelomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024March 29, 2024 | globenewswire.comUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.March 26, 2024 | globenewswire.comTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 22, 2024 | globenewswire.comTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26thMarch 14, 2024 | globenewswire.comTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal ScienceMarch 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 5, 2024 | globenewswire.comMichael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age ReversalSee More Headlines Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CUSIPN/A CIK1971532 Webtelomirpharma.com Phone(737)-289-0835FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares29,610,000Free FloatN/AMarket Cap$114.89 million OptionableN/A BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Christopher C. Chapman Jr. (Age 71)M.D., Co-Founder, Chairman & CEO Mr. Nathen Fuentes CPA (Age 41)CFO, Treasurer, & Secretary Comp: $66.15kDr. Francis E. O'Donnell Jr.M.D., Co-founder, Chief Medical Officer & Special AdvisorKey CompetitorsHeron TherapeuticsNASDAQ:HRTXOculisNASDAQ:OCSEsperion TherapeuticsNASDAQ:ESPRQ32 BioNASDAQ:QTTBCryoportNASDAQ:CYRXView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 50,165 shares on 7/26/2024Ownership: 0.169%Suncoast Equity ManagementBought 24,391 shares on 5/2/2024Ownership: 0.082%View All Institutional Transactions TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $5.00 at the beginning of 2024. Since then, TELO stock has decreased by 22.4% and is now trading at $3.88. View the best growth stocks for 2024 here. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments acted as the underwriter for the IPO. When does Telomir Pharmaceuticals' lock-up period expire? Telomir Pharmaceuticals' lock-up period expires on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its public offering on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. After the end of Telomir Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Who are Telomir Pharmaceuticals' major shareholders? Telomir Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.17%). How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TELO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
